

CHINA PHARMA HOLDINGS, INC.  
Form 10-Q  
August 11, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2009

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: 000-29523

**China Pharma Holdings, Inc.**

(Exact name of registrant as specified on its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

73-1564807

(IRS Employer Identification No.)

2<sup>nd</sup> Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China

(Address of principle executive offices)

570216

(Zip Code)

0086-898-66811730 (China)

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10-Q

As of August 10, 2009, 42,278,938 shares of China Pharma Holdings, Inc. common stock, par value \$0.001 per share, were outstanding.

---

**China Pharma Holdings, Inc.**

**TABLE OF CONTENTS**

Part I	Financial Information	1
Item 1.	Financial Statements	1
	Condensed Consolidated Balance Sheets as of June 30, 2009 and December 31, 2008 (Unaudited)	1
	Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2009 and 2008 (Unaudited)	2
	Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended June 30, 2009 and 2008 (Unaudited)	3
	Notes to Condensed Consolidated Financial Statements (Unaudited)	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	7
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 4.	Controls and Procedures	13
Part II	Other Information	14
Item 1	Legal Proceedings	14
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	14
Item 3	Defaults upon Senior Securities	14
Item 4	Submission of Matters to a Vote of Security Holders	14
Item 5	Other Information	14
Item 6	Exhibits	14
	Signatures	15

## PART I FINANCIAL INFORMATION

## ITEM 1. Financial Statements

**CHINA PHARMA HOLDINGS, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**

(Unaudited)

	June 30, 2009	December 31, 2008
<b>ASSETS</b>		
<b>Current Assets:</b>		
Cash and cash equivalents	\$ 3,642,801	\$ 6,927,149
Trade accounts receivable, less allowance for doubtful accounts of \$5,248,967 and \$4,474,175, respectively	42,854,941	36,008,095
Other receivables, less allowance for doubtful accounts of \$5,257 and \$54,242, respectively	90,060	163,957
Advances to suppliers	2,332,025	3,031,694
Inventory	14,874,358	13,139,750
Deferred tax assets	577,965	461,596
<b>Total Current Assets</b>	<b>64,372,150</b>	<b>59,732,241</b>
<b>Non-current Assets:</b>		
Property and equipment, net of accumulated depreciation of \$1,709,868 and \$1,483,267, respectively	6,755,629	6,738,368
Intangible assets, net of accumulated amortization of \$904,317 and \$547,567, respectively	8,145,249	6,162,549
Advances for purchases of intangible assets and property and equipment	6,655,560	2,838,679
<b>Total Non-current Assets</b>	<b>21,556,438</b>	<b>15,739,596</b>
<b>TOTAL ASSETS</b>	<b>\$ 85,928,588</b>	<b>\$ 75,471,837</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>Current Liabilities:</b>		
Trade accounts payable	\$ 3,476,675	\$ 1,049,268
Accrued expenses	59,284	56,075
Accrued taxes payable	1,090,162	1,170,003
Other payables	50,683	42,813
Advances from customers	730,848	693,178
Other payables - related parties	75,741	75,741
Short-term notes payable	2,483,637	2,480,231
<b>Total Current Liabilities</b>	<b>7,967,030</b>	<b>5,567,309</b>
Long term research and development commitments	36,524	36,474
<b>Total Liabilities</b>	<b>8,003,554</b>	<b>5,603,783</b>
<b>Stockholders' Equity:</b>		
Common stock, \$0.001 par value; 60,000,000 shares authorized; 42,278,938 shares issued and outstanding	42,279	42,279
Additional paid-in capital	21,066,338	21,066,338

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10-Q

Retained earnings	51,003,610	43,039,819
Accumulated comprehensive income - foreign currency translation adjustment	5,812,807	5,719,618
<b>Total Stockholders' Equity</b>	77,925,034	69,868,054
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<b>\$ 85,928,588</b>	<b>\$ 75,471,837</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**CHINA PHARMA HOLDINGS, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**AND COMPREHENSIVE INCOME**

**(Unaudited)**

	<b>For the three months ended June 30,</b>		<b>For the six months ended June 30,</b>	
	<b>2009</b>	<b>2008</b>	<b>2009</b>	<b>2008</b>
Revenue	\$ 13,601,355	\$ 11,278,803	\$ 26,593,337	\$ 22,995,848
Cost of revenue	7,681,845	5,325,992	14,745,072	11,235,760
Gross profit	5,919,510	5,952,811	11,848,265	11,760,088
Operating expenses:				
Selling expenses	603,924	456,630	1,206,684	794,422
General and administrative	553,607	565,772	1,041,654	914,165
Bad debt expense, net of recoveries	(40,147)	612,413	734,785	1,079,813
Total operating expenses	1,117,384	1,634,815	2,983,123	2,788,400
Income from operations	4,802,126	4,317,996	8,865,142	8,971,688
Non-operating income (expenses):				
Interest income	10,720	5,035	21,309	5,035
Interest expense	(40,471)	(50,440)	(78,707)	(95,713)
Total non-operating income (expense)	(29,751)	(45,405)	(57,398)	(90,678)
Income before taxes	4,772,375	4,272,591	8,807,744	8,881,010
Income tax expense	(486,231)	(235,292)	(843,953)	(653,170)
Net income	\$ 4,286,144	\$ 4,037,299	\$ 7,963,791	\$ 8,227,840
Basic and diluted earnings per share	\$ 0.10	\$ 0.10	\$ 0.19	\$ 0.22
Basic and diluted weighted average shares outstanding	42,278,938	38,982,235	42,278,938	38,130,586
Net income	\$ 4,286,144	\$ 4,037,299	\$ 7,963,791	\$ 8,227,840
Foreign currency translation adjustments	5,698	974,800	93,189	2,720,042
Comprehensive income	\$ 4,291,842	\$ 5,012,099	\$ 8,056,980	\$ 10,947,882

The accompanying notes are an integral part of these condensed consolidated financial statements.



## CHINA PHARMA HOLDINGS, INC.

## CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited)

	For the six months ended June 30,	
	2009	2008
<b>Cash Flows from Operating Activities:</b>		
Net income	\$ 7,963,791	\$ 8,227,840
Depreciation and amortization	558,866	332,077
Compensation paid with warrants	--	120,042
Changes in assets and liabilities:		
Trade accounts receivable	(6,798,955)	(7,358,577)
Other receivables	74,139	(371,696)
Advances to suppliers	703,994	(3,231,357)
Inventory	(1,716,958)	390,430
Deferred tax assets	(115,762)	(171,030)
Trade accounts payable	2,426,525	282,790
Accrued expenses	3,133	(117,176)
Accrued taxes payable	(81,466)	852,319
Other payables	7,819	(57,543)
Advances from customers	36,727	216,039
<b>Net Cash from Operating Activities</b>	<b>3,061,853</b>	<b>(885,842)</b>
<b>Cash Flows from Investing Activities:</b>		
Purchase of property and equipment	(232,624)	(16,683)
Purchase of intangible assets	(2,308,941)	(424,170)
Advances for purchases of intangibles and property and equipment	(3,813,857)	(2,269,286)
<b>Net Cash from Investing Activities</b>	<b>(6,355,422)</b>	<b>(2,710,139)</b>
<b>Cash Flows from Financing Activity:</b>		
Proceeds from sale of common stock and warrants		9,268,938
Payments of short term notes payable	--	(381,753)
<b>Net Cash from Financing Activity</b>	<b>--</b>	<b>8,887,185</b>
Effect of Exchange Rate Changes on Cash	9,221	(84,465)
<b>Net Increase (Decrease) in Cash and Cash Equivalents</b>	<b>(3,284,348)</b>	<b>5,206,739</b>
Cash and Cash Equivalents at Beginning of Period	6,927,149	1,830,335
<b>Cash and Cash Equivalents at End of Period</b>	<b>\$ 3,642,801</b>	<b>\$ 7,037,074</b>
<b>Supplemental Cash Flow Disclosure:</b>		
Cash paid for interest	\$ 85,429	\$ 143,893
Cash paid for income taxes	1,115,831	422,553

The accompanying notes are an integral part of these condensed consolidated financial statements.

**CHINA PHARMA HOLDINGS, INC.**  
**UNAUDITED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE THREE MONTHS ENDED JUNE 30, 2009**

**NOTE 1 - BASIS OF PRESENTATION**

The accompanying unaudited condensed consolidated financial statements of China Pharma Holdings, Inc. and its subsidiaries (the Company) were prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. Management of the Company (Management) believes that the following disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008.

These unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) that, in the opinion of Management, are necessary to present fairly the consolidated financial position and results of operations of the Company for the periods presented. Operating results for the six months ended June 30, 2009 are not necessarily indicative of the results that may be expected for the year ending December 31, 2009.

**Nature of Operations** – Through Hainan Helpson Medical & Biotechnology Co. Ltd., a wholly-owned subsidiary (Helpson), the Company manufactures and markets a diverse product portfolio of Western and Chinese medicines sold mainly to hospitals and private retailers in The People's Republic of China (the PRC), through its marketing department located in Hainan Province. There are also sixteen other offices, with sales representatives in other provinces and cities throughout the PRC.

**Accounting Estimates** - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

**Basic and Diluted Earnings per Common Share** - Basic and diluted earnings per common share are computed by dividing net income by the weighted-average number of common shares outstanding. As of June 30, 2009 and 2008, potentially dilutive securities includes warrants outstanding to purchase a total of 2,969,607 shares and 2,952,941 shares, respectively, of Company common stock with exercise prices ranging from \$2.38 to \$3.60 per share. These potentially issuable shares were not included in the compensation of diluted earnings per share as their effect would have been anti-dilutive.

**NOTE 2 - INVENTORY**

Inventory consisted of the following:

	<b>June 30, 2009</b>	<b>December 31, 2008</b>
Raw materials	\$ 7,982,606	\$ 10,836,039
Work in process	145,071	111,867
Finished goods	6,746,681	2,191,844
<b>Total Inventory</b>	<b>\$ 14,874,358</b>	<b>\$ 13,139,750</b>

**NOTE 3 - PROPERTY AND EQUIPMENT**

Property and equipment consisted of the following:

4

---

	June 30, 2009	December 31, 2008
Permit of land use	\$ 411,506	\$ 410,942
Buildings	2,226,967	1,871,206
Plant, machinery and equipment	4,521,229	1,497,004
Motor vehicle	135,389	135,204
Office equipment	117,600	106,918
Construction in progress	1,052,806	4,200,361
<b>Total</b>	<b>8,465,497</b>	<b>8,221,635</b>
Less: accumulated depreciation	(1,709,868)	(1,483,267)
<b>Property and Equipment, net</b>	<b>\$ 6,755,629</b>	<b>\$ 6,738,368</b>

Construction in progress consists of machinery and construction supplies that have been paid for, but are not yet completed and placed into production. Once the machinery is working or the facility in use, it is moved into plant, machinery and equipment and depreciated. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

Asset	Life - years
Permit of land use	40 - 70
Buildings	20 - 35
Plant, machinery and equipment	10
Motor vehicle	5 - 10
Office equipment	5

For the six months ended June 30, 2009 and 2008, depreciation expense was \$224,615 and \$201,645, respectively. Depreciation on construction-in-process begins once the asset has been put into service.

#### **NOTE 4 - INTANGIBLE ASSETS**

Intangible assets represent the costs of patents, trademarks, licenses, techniques and formulas. Amortization of intangible assets was \$334,250 and \$130,432 for the six months ended June 30, 2009 and 2008, respectively. SFDA-certified medical formulas are amortized over the expected life of the related medicine once production and sales commence.

#### **NOTE 5 – ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS AND PROPERTY AND EQUIPMENT**

In order to expand the number of medicines manufactured and marketed by the Company, the Company has entered into purchase contracts with independent and university laboratories. The contracts are for the purchase of established medical formulas for which the related patents have expired (generic medicines). Prior to entering into the contracts, the independent laboratories typically have completed all required research and development to determine the medical formula for and the method of production of the generic medicine. If the Company enters into a contract prior to the determination of the medical formula for a medicine, contract costs incurred to establish the medical formula are recognized as research and development expense. The contracts with the laboratories are primarily for certification of the manufacturing process and authorization by the State Food and Drug Administration (the SFDA) to sell the generic medicines. Costs incurred under the contracts for SFDA certification are capitalized as advances for purchases of intangible assets. Under the terms of each contract, the Company is required to make progress payments to the laboratory; however, the payments are fully refundable in the event that the laboratory fails to obtain SFDA certification of the generic medicine under the contract.

The Company is also increasing production capabilities with new machinery and facilities. As is common in the PRC, the Company prepays for much of the machinery and construction supplies. The prepayments are capitalized as advances for purchases of property and equipment until the construction begins or the machinery is delivered to the Company.

**NOTE 6 – SHORT-TERM NOTES PAYABLE**

On December 24, 2008 the Company entered into a note payable for a line of credit with the bank collateralized by certain land use rights, buildings, machinery and equipment. The outstanding advance made under the line of credit was \$2,483,637 and \$2,420,894 at June 30, 2009 and December 31, 2008, respectively, bears interest at a rate of 6.372% and matures on November 23, 2009. The loan is personally guaranteed by Ms. Zhilin Li, the Company's Chief Executive Officer. No additional compensation was paid to Ms. Li for her guarantee of the note payable.

**NOTE 7 - INCOME TAXES**

The Company accounts for its income taxes in accordance with SFAS No. 109, which requires recognition of deferred tax assets and liabilities and any tax credit carry forwards available. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Undistributed earnings of Helpson, the Company's foreign subsidiary, since its acquisition, amounted to approximately \$48.4 million at June 30, 2009. Those earnings, as well as the investment in Helpson of approximately \$17 million are considered to be indefinitely reinvested and, accordingly, no U.S. federal and state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to both U.S. income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.

Under current tax law in China, the Company will be subject to the following enterprise income tax rates:

Year	Enterprise Income Tax Rate
2009	10%
2010	11%
2011	24%
2012 and after	25%

The Company has also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

**NOTE 8 - STOCKHOLDERS' EQUITY**

The Company has outstanding warrants to purchase an aggregate of 2,969,607 shares of Company's common stock at exercise prices ranging from \$2.38 to \$3.60 per share, which expire from January 29, 2010 through December 23, 2011.

**NOTE 9 - CONTINGENCIES**

**Economic environment** - Significantly all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected

by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company's operations.

In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

#### **NOTE 10 – CONCENTRATIONS**

At June 30, 2009, one customer accounted for 12.0% of accounts receivable.

For the six months ended June 30, 2009, three customers accounted for 23.6%, 18.1% and 12.6% of sales, respectively. For the six months ended June 30, 2008, three customers accounted for 16.8%, 13.7% and 10.3% of sales, respectively.

For the six months ended June 30, 2009, purchases from three suppliers accounted for 35.1%, 32.1% and 15.0% of raw material purchases, respectively. For the six months ended June 30, 2008, purchases from three suppliers accounted for 29.1%, 29.1% and 23.70% of raw material purchases, respectively.

#### **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion should be read in conjunction with China Pharma Holdings, Inc.'s ("China Pharma" or "the Company") consolidated financial statements and related notes included elsewhere in this Current Report on Form 10-Q.

*This filing contains forward-looking statements. The words "anticipated", "believe", "expect", "plan", "intend", "seek", "estimate", "project", "could", "may" and similar expressions are intended to identify forward-looking statements. These statements include, among others, information regarding future operations, future capital expenditures, and future net cash flow. Such statements reflect management's current views with respect to future events and financial performance and involve risks and uncertainties, including but not limited to changes in general economic and business conditions, changes in foreign, political, social, and economic conditions, regulatory initiatives and compliance with governmental regulations, the ability to increase market share, and various other matters, many of which are beyond China Pharma's control. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated or otherwise indicated. Consequently, all of the forward-looking statements made in this filing are qualified by these cautionary statements and there can be no assurance of the actual results or developments.*

##### **1. Business Overview**

China Pharma Holdings, Inc. is a fast growing specialty pharmaceutical company dedicated to providing high-quality branded and branded-generic products for a wide range of high incidence and high mortality conditions in China. We have a strong focus on bringing new and generic medicines to market through in-house R&D and also through purchasing of medical formulas with many institutions. Over the past 15 years we have successfully commercialized 19 products with approvals from the SFDA.

Our diverse portfolio includes products for treatment of central nervous system diseases, cerebral and cardio vascular disorders, infectious diseases and respiratory and digestive illnesses. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable Goods Manufacturing Practice (GMP) certified production lines covering our major dosage forms or products. Our broad and expanding distribution network covers 30 provinces, municipalities and autonomous regions in China. Hainan Helpson Medical & Biotechnology Co., Ltd (Helpson), located in Haikou City in Hainan Province, China, is the main operating unit and a wholly owned subsidiary of China Pharma Holdings, Inc. The Company is registered in Delaware, USA.



## Proven Record of Success

- u 2008: granted GMP 5-year re-certification
- u January 2008: Bumetanine was approved by the SFDA and taken to market
- u May 2008: completed \$10 million PIPE financing
- u Second half of 2008: began Dry Powder Capacity expansion
- u October 2008: New antibiotic formula received SFDA approval to enter clinical trials
- u January 2009: Liver disease product, Tiopronin, received SFDA production approval
- u February 2009: Anti-hypertension drug, Candesartan, received SFDA approval to enter clinical trials
- u June 2009: Rosuvastatin (a generic form of Crestor, for indication of high blood cholesterol level), received SFDA approval to enter clinical trials.

**Strategy for Growth** – We are positioned in a rapidly growing industry in the fastest growing economy in the world. Furthermore, the recently announced Healthcare Reform in China implies significant additional revenue opportunities for pharmaceutical enterprises supported by government initiatives. The increase in demand from these sources should allow us to grow organically at a healthy pace. In addition, the new products from our pipeline (such as the generic version of Crestor) presents us with growth opportunities once these products come on line. Finally, the Healthcare Reform will change the current landscape of the Chinese pharmaceutical industry which we think will create many attractive acquisition opportunities. We plan to use these opportunities to the fullest extent possible and hope to continue our rate of growth in the future.

**Strong Revenue Growth and High Margins** - We have experienced a compounded, annual growth-rate of over 68% in sales of our therapeutics since 2003. Our historical gross profit margin has been at 40%-50%. Our comparatively flat marketing and selling network and distribution system has enabled us to keep our net income margin (net income as a percentage of total revenue) at between 30%-40%. We are able to compete in the highly competitive pharmaceutical industry through our diversified product line, cost control measures and a strong sales network. Our experienced management team, market insights, and strong, in-house and collaborative third-party research resources enable us to develop and launch new and improved generic products based on market demand.

## 2. Recent Developments

As announced previously, we launched Tiopronin, our new drug for hepatitis, during this quarter. So far the sales pace of Tiopronin is progressing as planned, generating approximately \$500,000 in revenue during the second quarter (Q2). During the quarter we also announced that China Pharma entered into a purchase contract for Rosuvastatin, a generic form of Crestor for treating high cholesterol levels in patients with Hyperlipidemia that has been accepted for clinical trials. Because of the large number of patients currently suffering from high cholesterol, we anticipate that the market will be strong for this product. We anticipate the trial will be completed mid-year 2010.

We made significant improvement in our account receivable collections during the second quarter compared to the previous quarter. While our accounts receivable remain quite large at the present time, collections continue to be a focus of management and we expect further improvement in the quarters ahead.

### **3. Market Trends**

The growth of China's pharmaceutical market is driven by China's rapid economic growth. Increased healthcare spending by the Chinese Government to reform the healthcare system has already greatly improved the accessibility to and desire for medical care. Important additional factors include: the aging of the population and the resulting increase in age-related disorders; the urban migration of the population; and improved awareness of self-health care. According to Intercontinental Marketing Services (IMS) forecasts, China will become the seventh largest pharmaceutical market in the world in 2009 and the second largest in 2020, with a market capacity of \$220 billion.

The recent healthcare reform program announced by the Chinese Government will have a real and significant impact on all healthcare related industries in China, including the pharmaceutical industry. While the plans are still in draft format, we think the principal strategy is fairly clear. Over all, the government plans to provide a basic, universal healthcare system to all citizens of China. Pharmaceutical companies will be impacted most by the proposed Essential Drug List on which the government will publish the most often used drugs. It is assumed that there will be strict price control on these basic drugs, although the volume of sales will likely increase. We believe the effect of the reform will be significant if not immediate. We are making ourselves more nimble and are ready to adjust our marketing and product strategy according to the new environment when it becomes a reality. We are adjusting our sales and marketing strategy, to further penetrate the lower-tier healthcare facilities market which is one of the focuses of the current healthcare reform.

#### 4. Results of Operations

The following table presents the results of operations of the Company for the three months ended June 30, 2009 and 2008; both are given in US dollars.

##### Results of Operations

	3 Months ended June 30,	
	2009	2008
Revenue	\$ 13,601,355	\$ 11,278,803
Cost of Revenue	7,681,845	5,325,992
Gross Profit	5,919,510	5,952,811
Selling Expenses	603,924	456,630
General and Admin Expenses	553,607	565,772
Bad Debt Expense	(40,147)	612,413
Income from Operations	4,802,126	4,317,996
Interest Income	10,720	5,035
Interest Expense	(40,471)	(50,440)
Income Tax Expense	486,231	235,292
Net Income	\$ 4,286,144	\$ 4,037,299
Net Income per Share	\$ 0.10	\$ 0.10

##### Revenue

For the three months ended June 30, 2009, we saw an increase of 21% in year-over-year revenue to \$13.6 million. This is an increase of \$2.3 million from the \$11.3 million we generated in the corresponding period of 2008.

Notably, Q2 sales of Anti-Viro/Infection product category rose 91% over the same period a year ago to approximately \$5.2 million. Our CNS and Cerebral & Cardio Vascular drugs saw a more steady sales increase of 4% during the second quarter to \$5.1 million. Our Other Products category (including our tumor drug Granisetron and various other products) saw an increase of 36% over last year to \$2.3 million. Our Digestive product sales rose by 101% to \$0.94 million, mainly due to the sales contribution from our new product Tiopronin. During this quarter we saw Tiopronin generating close to \$500,000 in sales. This is very much tracking as planned.

##### Cost of Revenue

For the three months ended June 30, 2009, Cost of Revenue was approximately \$7.7 million or 56% of total revenue, compared to the corresponding period of 2008, which was \$5.3 million or 47% of total revenue. The higher total cost of revenue was mainly due to a higher volume of lower margin products sold.



### **Gross Profit**

Gross Profit for the three months ended June 30, 2009 was \$5.92 million, or 44% of total revenue. This is about flat compared to the \$5.95 million or 53% of total revenue for the second quarter of 2008. The lower gross profit margin in the second quarter of 2009 was mainly due to a higher volume of lower margin products sold.

### **Selling Expense**

The selling expense of the three months ended June 30, 2009 was approximately \$0.6 million, an increase of approximately \$0.15 million, or 32%, compared to approximately \$0.46 million of the three months ended June 30, 2008. The main reason for this increase was our investing in our distribution channels and marketing of our products.

### **G & A Expenses**

The general and administrative expenses of the three months ended June 30, 2009 decreased to approximately \$0.55 million, a decrease of \$0.1 million, or 2%, compared to \$0.566 million for the same period in 2008. This decrease reflects lower operating expenses that occurred as a result of expanded business operations.

### **Bad Debt Expense**

For the three months ended June 30, 2009, we recorded a small net recovery of bad debt.

Management believes that the amount of allowance for doubtful accounts as of the beginning of the quarter (\$5.2 million) is adequate for our current accounts receivable. Management will continue to monitor the adequacy of the bad debt allowance.

As to the peculiarity of the Chinese pharmaceutical market environment, deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are a normal phenomenon. Over 90% of our drugs are sold to state-owned hospitals and local medicine distributors, which creates slow collections of our trade receivables. Since the majority of hospitals in China are backed by the government, management believes that the deferred payments from state-owned hospitals are secure and will eventually be collected. So far, China Pharma has not lost any receivables in its 15 years history of doing business with hospitals.

### **Income from Operation**

The operating income for the three months ended June 30, 2009 is approximately \$4.80 million, compared to \$4.32 million for the same period in 2008, an increase of \$0.48 million, or 11%. The reasons for the higher operating income in Q2 2009 are higher revenue, lower G&A cost and lower bad-debt expense.

### **Interest Income**

The interest income for the three months ended June 30, 2009 is \$10,720 from our bank deposit. In the second quarter of 2008 we had interest income of \$5,035.

### **Interest Expense**

Interest expense for the three months ended June 30, 2009 is approximately \$40,471, compared to \$50,440 of the same period of 2008.

### **Income Tax Expense**

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10-Q

Enterprise income tax expense for the three months ended June 30, 2009 was \$486,231, while the second quarter 2008 income tax expense was \$235,292. We have been granted a 'tax holiday' with a favorable rate of 50% of the tax rate. This year we pay our enterprise income tax at the rate of 10% while our tax rate in 2008 was 9%.

## Net Income

The net income for the three months ended June 30, 2009, excluding the effect of foreign exchange transactions, was approximately \$4.29 million, which was \$0.25 million higher than that for the three months ended June 30, 2008, of approximately \$4.04 million. This is an increase of about 6%. For the three months ended June 30, 2009, earnings per common share is \$0.10 per share which matched that of Q2 2008. While our Q2 total Net Income increased compare to the same period in 2008, shares outstanding also increased from our PIPE financing activity in 2008.

## 5. Liquidity and Capital Resources

Our principal sources of liquidity are cash generated from operations and short term bank loans. As of June 30, 2009, cash and cash equivalents were \$3,642,801, a decrease of \$3.28 million from \$6,927,149 as of December 31, 2008. This was primarily due to our investing activities being more than the cash provided by operating activities.

During the second quarter of 2009, we were able to improve our operating cash flow compared to the previous quarter by vigorously collecting on our outstanding accounts receivable. Our effort resulted in a substantial increase in the amount of collection compared to our first quarter. While we have made progress, improving AR collection continues to be a focus of the management team and we expect to make further progress in the quarters to come.

In addition, the company is in the process of negotiating with our local banker to increase the amount of short term financing available to us.

Based on our current operating plan, management believes that cash generation from operations plus bank loans will be sufficient to meet our working capital and current R&D requirements plus new product contracts in the foreseeable future. However, if events or circumstances occur and we do not meet our operating plan as expected, we may be required to seek additional capital and/or reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives. We may seek additional financing, which may include debt and/or equity financing. There can be no assurance that any additional financing will be available on acceptable terms, if at all. Any equity financing may result in dilution to existing stockholders and any debt financing may include restrictive covenants.

### Cashflows for 6 Months ended June 30, 2009 and 2008

	6 Months ended June 30,	
	2009	2008
Net Cash Provided (Used by) Operating Activities	\$ 3,061,853	\$ (885,842)
Net Cash Used in Investing Activities	(6,355,422)	(2,710,139)
Net Cash Provided by Financing Activities	-	8,887,185
Effect of Exchange Rate change on Cash	9,221	(84,465)
Cash & Equivalent Beginning Balance	6,927,149	1,830,335
Cash & Equivalent Ending Balance	\$ 3,642,801	\$ 7,037,074

### Operating Activities:

Net Cash provided (used) by operating activities was \$3.1 million in the six month period ended June 30, 2009 compared to (\$0.89) million for the same period in 2008, an increase of \$3.95 million. The difference was due to better account receivable collection and other improvements in working capital management in 2009.



*Investing Activities:*

Net cash used in investing activities in the six months ended June 30, 2009 was \$6.36 million. Majority of this was for our investment in a number of new drug formulas during the first half of 2009. This is an increase of \$3.6 million from the same period in 2008 of \$2.7 million.

*Financing Activities:*

We did not have any financing activities during the six months ended June 30, 2009 while we raised approximately \$9 million in a PIPE transaction in May of 2008.

**6. Off-Balance Sheet Arrangements**

There were no off-balance sheet arrangements during the three months ended June 30, 2009.

**7. Commitments**

At June 30, 2009, the Company had no material commitments for capital expenditures other than for those expenditures incurred in the ordinary course of business.

**8. Recently Enacted Accounting Pronouncements**

In September 2006, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 157, Fair Value Measurements, which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. In February 2008, the FASB issued FASB Staff Position (FSP FIN) No. 157-2 which extended the effective date for certain nonfinancial assets and nonfinancial liabilities to fiscal years beginning after November 15, 2008. The Company does not expect the adoption of SFAS No. 157 to have a material impact on our consolidated financial statements.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities. SFAS No. 159 permits companies to choose to measure many financial instruments and certain other items at fair value. SFAS No. 159 is effective for financial statements issued for fiscal years beginning after November 15, 2007. The Company does not expect the adoption of SFAS No. 159 to have a material impact on our consolidated financial statements.

In June 2007, the Emerging Issues Task Force of the FASB issued EITF Issue No. 07-3, "Accounting for Nonrefundable Advance Payments for Goods or Services to be Used in Future Research and Development Activities", ("EITF 07-3") which is effective for fiscal years beginning after December 15, 2007. EITF 07-3 requires that nonrefundable advance payments for future research and development activities be deferred and capitalized. Such amounts will be recognized as an expense as the goods are delivered or the related services are performed. EITF 07-3 is not expected to have a material impact on our results of operations or financial position.

In December 2007, the FASB issued SFAS No. 141(R), Business Combinations, and SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements. SFAS No. 141(R) requires an acquirer to measure the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree at their fair values on the

acquisition date, with goodwill being the excess value over the net identifiable assets acquired. SFAS No. 160 clarifies that a non-controlling interest in a subsidiary should be reported as equity in the consolidated financial statements, consolidated net income shall be adjusted to include the net income attributed to the non-controlling interest and consolidated comprehensive income shall be adjusted to include the comprehensive income attributed to the non-controlling interest. The calculation of earnings per share will continue to be based on income amounts attributable to the parent. SFAS No. 141(R) and SFAS No. 160 are effective for financial statements issued for fiscal years beginning after December 15, 2008. Early adoption is prohibited. The Company has not yet determined the effect on our consolidated financial statements, if any, upon adoption of SFAS No. 141(R) or SFAS No. 160.

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities. SFAS No. 161 amends SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities to require enhanced disclosures concerning the manner in which an entity uses derivatives (and the reasons it uses them), the manner in which derivatives and related hedged items are accounted for under SFAS No. 133 and interpretations thereof, and the effects that derivatives and related hedged items have on an entity's financial position, financial performance, and cash flows. SFAS No. 161 is effective for financial statements of fiscal years and interim periods beginning after November 15, 2008. The Company has not yet determined the effects on its consolidated financial statements, if any, that may result upon the adoption of SFAS 161.

In May 2008, The US Financial Accounting Standards Board (FASB) and the International Accounting Standards Board (IASB) published consultative documents that seek public comment on two of the eight phases of their joint project to develop an improved conceptual framework. The objective of the project is to develop an improved conceptual framework that provides a sound foundation for developing future accounting standards. Further, in June 2008, The Financial Accounting Standards Board (FASB) issued an Exposure Draft (ED) of a proposed Statement of Financial Accounting Standards, Disclosure of Certain Loss Contingencies--an amendment of FASB Statements No. 5 and 141(R). The proposed Statement would be effective for fiscal years ending after December 15, 2008, and interim and annual periods in subsequent fiscal years. In addition, on June 06, 2008, the Financial Accounting Standards Board (FASB) issued an Exposure Draft (ED) of a proposed Statement of Financial Accounting Standards, Accounting for Hedging Activities--an amendment of FASB Statement No. 133. The proposed Statement would require application of the amended hedging requirements for financial statements issued for fiscal years beginning after June 15, 2009, and interim periods within those fiscal years.

### **Item 3 – Quantitative and Qualitative Disclosures About Market Risks**

The Company is subject to certain market risks, including changes in interest rates and currency exchange rates. The Company does not undertake any specific actions to limit those exposures.

### **Item 4 - Controls and Procedures**

#### **Evaluation of Disclosure Controls and Procedures**

Our Chief Executive Officer and our Chief Financial Officer, after evaluating the effectiveness of the Company's "disclosure controls and procedures" (as defined in the Securities Exchange Act of 1934 (Exchange Act) Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report, has concluded that our disclosure controls and procedures were effective based on their evaluation of these controls and procedures required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.

#### **Changes in Internal Controls over Financial Reporting**

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and (b) is accumulated and communicated to management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

A system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the system will meet its objectives. The design of a control system is based, in part, upon the benefits of the

control system relative to its costs. Control systems can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. In addition, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. In addition, the design of any control system is based in part upon assumptions about the likelihood of future events.

## **PART II. OTHER INFORMATION**

### **Item 1 Legal Proceedings**

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceeding or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

### **Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds**

None.

### **Item 3 - Defaults upon Senior Securities**

None.

### **Item 4 - Submission of Matters to a Vote of Security Holders**

On April 28, 2009, a majority of the outstanding shares of voting capital stock approved to elect Heung Mei Tsui as a new member of the board of directors of the Company. The shareholder approval was granted by written consent, in lieu of a special meeting of the shareholders. In order to provide information to our shareholders regarding this action, we filed a definitive information statement with the Securities and Exchange Commission on June 25, 2009 and delivered it to our shareholders of record as of the close of business on April 28, 2009.

### **Item 5 - Other Information**

None.

### **Item 6 - Exhibits**

The following exhibits are filed herewith:

31.1 – Certification pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 – Certification pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 – Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 – Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.



**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**China Pharma Holdings, Inc.**

Dated: August 10, 2009

/s/ Zhilin Li  
Zhilin Li  
Chief Executive Officer,  
President and Director

Dated: August 10, 2009

/s/ Frank Waung  
Frank Waung  
Chief Financial Officer

